Cargando…
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
BACKGROUND: The adoptive transfer of T cells redirected to tumor via chimeric antigen receptors (CARs) has produced clinical benefits for the treatment of hematologic diseases. To extend this approach to breast cancer, we generated CAR T cells directed against mucin1 (MUC1), an aberrantly glycosylat...
Autores principales: | Bajgain, Pradip, Tawinwung, Supannikar, D’Elia, Lindsey, Sukumaran, Sujita, Watanabe, Norihiro, Hoyos, Valentina, Lulla, Premal, Brenner, Malcolm K., Leen, Ann M., Vera, Juan F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944113/ https://www.ncbi.nlm.nih.gov/pubmed/29747685 http://dx.doi.org/10.1186/s40425-018-0347-5 |
Ejemplares similares
-
Go-CART: an animal-free system for the assessment of CAR T cell function
por: Bajgain, Pradip, et al.
Publicado: (2015) -
Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity
por: Torres Chavez, Alejandro, et al.
Publicado: (2019) -
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
por: Nalawade, Saisha A, et al.
Publicado: (2021) -
Immunomodulatory effect of standardized C. asiatica extract on a promotion of regulatory T cells in rats
por: Tawinwung, Supannikar, et al.
Publicado: (2021) -
An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment
por: Khuisangeam, Nattarika, et al.
Publicado: (2022)